Involvement of Bacteria Other Than Clostridium difficile in Antibiotic-Associated Diarrhoea

Trends in Microbiology

Volumn 24, Issue 6, 2016, Pages 463-476

  Larcombe, Sarah ^a   Hutton, Melanie L ^a   Lyras, Dena ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Antibiotic resistance; Antibiotic associated diarrhoea; Antibiotics; Bacteria

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT; ENTEROTOXIN; VIRULENCE FACTOR;

AGE; ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM PERFRINGENS INFECTION; COMORBIDITY; GASTROINTESTINAL SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; KLEBSIELLA OXYTOCA; MIXED INFECTION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; CLOSTRIDIUM INFECTION; CROSS INFECTION; DIARRHEA; DRUG EFFECTS; KLEBSIELLA INFECTION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CLOSTRIDIUM PERFRINGENS; CROSS INFECTION; DIARRHEA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROTOXINS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA OXYTOCA; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE FACTORS;

EID: 84958559304     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2016.02.001     Document Type: Review

References (104)

1. Varughese C.A., et al. Antibiotic-associated diarrhea: a refresher on causes and possible prevention with probiotics - continuing education article. J. Pharm. Pract. 2013, 26:476-482.
2. Wilcox M.H. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract. Res. Clin. Gastroenterol. 2003, 17:475-493.
3. McFarland L.V. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008, 3:563-578.
4. Abrahao C., et al. Similar frequency of detection of Clostridium perfringens enterotoxin and Clostridium difficile toxins in patients with antibiotic-associated diarrhea. Eur. J. Clin. Microbiol. Infect. Dis. 2001, 20:676-677.
5. Asha N.J., et al. Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J. Clin. Microbiol. 2006, 44:2785-2791.
6. Avery L.M., et al. Case of antibiotic-associated diarrhea caused by Staphylococcus aureus enterocolitis. Am. J. Health Syst. Pharm. 2015, 72:943-951.
7. Borriello S.P., et al. Enterotoxigenic Clostridium perfringens: a possible cause of antibiotic-associated diarrhoea. Lancet 1984, 1:305-307.
8. Boyce J.M., Havill N.L. Nosocomial antibiotic-associated diarrhea associated with enterotoxin-producing strains of methicillin-resistant Staphylococcus aureus. Am. J. Gastroenterol. 2005, 100:1828-1834.
9. Carman R.J. Clostridium perfringens in spontaneous and antibiotic-associated diarrhoea of man and other animals. Rev. Med. Microbiol. 1997, 8:S43-S45.
10. Froberg M.K., et al. Staphylococcus aureus and Clostridium difficile cause distinct pseudomembranous intestinal diseases. Clin. Infect. Dis. 2004, 39:747-750.
11. Gravet A. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea Is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD. J. Clin. Microbiol. 1999, 37:4012-4019.
12. Heimesaat M.M., et al. Prevalence of Clostridium difficile toxins A and B and Clostridium perfringens enterotoxin A in stool samples of patients with antibiotic-associated diarrhea. Infection 2005, 33:340-344.
13. Hoffmann K.M., et al. Antibiotic-associated hemorrhagic colitis caused by cytotoxin-producing Klebsiella oxytoca. Pediatrics 2010, 125:e960-e963.
14. Högenauer C., et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 2006, 355:2418-2426.
15. Iwata K., et al. A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus. BMC Infect. Dis. 2014, 14:247.
16. Joainig M.M., et al. Cytotoxic effects of Klebsiella oxytoca strains isolated from patients with antibiotic-associated hemorrhagic colitis or other diseases caused by infections and from healthy subjects. J. Clin. Microbiol. 2010, 48:817-824.
17. Lo T.S., Borchardt S.M. Antibiotic-associated diarrhea due to methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2009, 63:388-389.
18. Modi N., Wilcox M.H. Evidence for antibiotic induced Clostridium perfringens diarrhoea. J. Clin. Pathol. 2001, 54:748-751.
19. Philbrick A.M., Ernst M.E. Amoxicillin-associated hemorrhagic colitis in the presence of Klebsiella oxytoca. Pharmacotherapy 2007, 27:1603-1607.
20. Wei Y., et al. Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect. Dis. 2015, 15:265.
21. Zollner-Schwetz I., et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin. Infect. Dis. 2008, 47:e74-e78.
22. Bartlett J.G. Antibiotic-associated diarrhea. Clin. Infect. Dis. 1992, 15:573-581.
23. Högenauer C., et al. Mechanisms and management of antibiotic-associated diarrhea. Clin. Infect. Dis. 1998, 27:702-710.
24. Owens R.C. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn. Microbiol. Infect. Dis. 2008, 61:110-128.
25. Wiström J., et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 2001, 47:43-50.
26. Robinson C.J., Young V.B. Antibiotic administration alters the community structure of the gastrointestinal microbiota. Gut Microbes 2010, 1:279-284.
27. McDonald L.C., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 2005, 353:2433-2441.
28. Borriello S.P., et al. Epidemiology of diarrhoea caused by enterotoxigenic Clostridium perfringens. J. Med. Microbiol. 1985, 20:363-372.
29. Flemming K., Ackermann G. Prevalence of enterotoxin producing Staphylococcus aureus in stools of patients with nosocomial diarrhea. Infection 2007, 35:356-358.
30. Samuel S.C., et al. An investigation into Clostridium perfringens enterotoxin-associated diarrhoea. J. Hosp. Infect. 1991, 18:219-230.
31. Williams R., et al. Diarrhoea due to enterotoxigenic Clostridium perfringens: clinical features and management of a cluster of ten cases. Age Aging 1985, 14:296-302.
32. Koga H., et al. Can quinolones cause hemorrhagic colitis of late onset?. Dis. Colon Rectum 1999, 42:1502-1504.
33. Dial S. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can. Med. Assoc. J. 2004, 171:33-38.
34. Dubberke E.R., et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin. Infect. Dis. 2007, 45:1543-1549.
35. Jayatilaka S., et al. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann. Clin. Lab. Sci. 2007, 37:241-247.
36. Vaishnavi C., et al. Cost-effective screening of pooled faecal specimens from patients with nosocomial diarrhoea for Clostridium perfringens enterotoxin. Indian J. Med. Microbiol. 2011, 29:56-59.
37. Yearsley K.A., et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment. Pharmacol. Ther. 2006, 24:613-619.
38. Vesper B.J., et al. The effect of proton pump inhibitors on the human microbiota. Curr. Drug Metab. 2009, 10:84-89.
39. Canani R.B., et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817-e820.
40. Tennant S.M., et al. Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. Infect. Immun. 2008, 76:639-645.
41. Agastya G., et al. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol. Immunotoxicol. 2000, 22:357-372.
42. Wandall J.H. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992, 33:617-621.
43. Zedtwitz-Liebenstein K., et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit. Care Med. 2002, 30:1118-1122.
44. Lowe C., et al. Outbreak of extended-spectrum beta-lactamase-producing Klebsiella oxytoca infections associated with contaminated handwashing sinks. Emerg. Infect. Dis. 2012, 18:1242-1247.
45. Sadsad R., et al. Effectiveness of hospital-wide methicillin-resistant Staphylococcus aureus (MRSA) infection control policies differs by ward specialty. PLoS ONE 2013, 8:e83099.
46. Zerey M., et al. The burden of Clostridium difficile in surgical patients in the United States. Surg. Infect. (Larchmt) 2007, 8:557-566.
47. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. 1998, 16:292-307.
48. Larson H.E., Borriello S.P. Infectious diarrhoea due to Clostridium perfringens. J. Infect. Dis. 1988, 157:390-391.
49. Nitzan O., et al. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J. Gastroenterol. 2013, 19:7577-7585.
50. Khor B., et al. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
51. Laukoetter M.G., et al. Role of the intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 2008, 14:401-407.
52. McGuckin M.A., et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 2009, 15:100-113.
53. Su L., et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009, 136:551-563.
54. Dupaul-Chicoine J., et al. Crosstalk between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease. Inflamm. Bowel Dis. 2013, 19:2227-2237.
55. Tamboli C.P., et al. Dysbiosis in inflammatory bowel disease. Gut 2004, 53:1-4.
56. Banaszkiewicz A., et al. Enterotoxigenic Clostridium perfringens infection and pediatric patients with inflammatory bowel disease. J. Crohns Colitis 2014, 8:276-281.
57. Nguyen G.C., et al. Increased prevalence of and associated mortality with methicillin-resistant Staphylococcus aureus among hospitalized IBD patients. Am. J. Gastroenterol. 2010, 105:371-377.
58. Joshy L., et al. Enterotoxigenic Clostridium perfringens and sporadic diarrhoea: a study from an Indian tertiary care hospital. J. Med. Microbiol. 2006, 55:1757-1758.
59. Pituch H., et al. Laboratory diagnosis of antibiotic-associated diarrhea: a Polish pilot study into the clinical relevance of Clostridium difficile and Clostridium perfringens toxins. Diagn. Microbiol. Infect. Dis. 2007, 58:71-75.
60. Leffler D.A., Lamont J.T. Clostridium difficile infection. N. Engl. J. Med. 2015, 372:1539-1548.
61. Rupnik M., et al. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009, 7:526-536.
62. Gorkiewicz G. Nosocomial and antibiotic-associated diarrhoea caused by organisms other than Clostridium difficile. Int. J. Antimicrob. Agents 2009, 33:37-41.
63. Li J., McClane B.A. Contributions of NanI sialidase to Caco-2 cell adherence by Clostridium perfringens type A and C strains causing human intestinal disease. Infect. Immun. 2014, 82:4620-4630.
64. Sarker M.R., et al. Inactivation of the gene (cpe) encoding Clostridium perfringens enterotoxin eliminates the ability of two cpe-positive C. perfringens type A human gastrointestinal disease isolates to affect rabbit ileal loops. Mol. Microbiol. 1999, 33:946-958.
65. Brynestad S., et al. The Clostridium perfringens enterotoxin gene is on a transposable element in type A human food poisoning strains. Microbiology 1997, 143:2109-2115.
66. Collie R.E., McClane B.A. Evidence that the enterotoxin gene can be episomal in Clostridium perfringens isolated associated with non-food-borne human gastrointestinal diseases. J. Clin. Microbiol. 1998, 36:30-36.
67. Sparks S.G., et al. Genotyping of enterotoxigenic Clostridium perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. J. Clin. Microbiol. 2001, 39:883-888.
68. Miyamoto K., et al. Complete sequencing and diversity analysis of the enterotoxin-encoding plasmids in Clostridium perfringens type A non-food-borne human gastrointestinal disease isolates. J. Bacteriol. 2006, 188:1585-1598.
69. McClane B.A. The complex interactions between Clostridium perfringens enterotoxin and epithelial tight junctions. Toxicon 2001, 39:1781-1791.
70. Smedley J.G., et al. The enteric toxins of Clostridium perfringens. Rev. Physiol. Biochem. Pharmacol. 2004, 152:183-204.
71. Briggs D.C., et al. Structure of the food-poisoning Clostridium perfringens enterotoxin reveals similarity to the aerolysin-like pore-forming toxins. J. Mol. Biol. 2011, 413:138-149.
72. Paredes-Sabja D., Sarker M.R. Clostridium perfringens sporulation and its relevance to pathogenesis. Future Microbiol. 2009, 4:519-525.
73. Förster C. Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 2008, 130:55-70.
74. Robertson S.L., et al. Compositional and stoichiometric analysis of Clostridium perfringens enterotoxin complexes in Caco-2 cells and claudin 4 fibroblast transfectants. Cell. Microbiol. 2007, 9:2734-2755.
75. Chakrabarti G., McClane B.A. The importance of calcium influx, calpain and calmodulin for the activation of CaCo-2 cell death pathways by Clostridium perfringens enterotoxin. Cell. Microbiol. 2005, 7:129-146.
76. Chakrabarti G., et al. Death pathways activated in CaCo-2 cells by Clostridium perfringens enterotoxin. Infect. Immun. 2003, 71:4260-4270.
77. Smedley J.G., et al. Noncytotoxic Clostridium perfringens enterotoxin (CPE) variants localize CPE intestinal binding and demonstrate a relationship between CPE-induced cytotoxicity and enterotoxicity. Infect. Immun. 2008, 76:3793-3800.
78. Garcia J.P., et al. Clostridium perfringens type A enterotoxin damages the rabbit colon. Infect. Immun. 2014, 82:2211-2218.
79. Fernandez Miyakawa M.E., et al. Clostridium perfringens enterotoxin damages the human intestine in vitro. Infect. Immun. 2005, 73:8407-8410.
80. Prohaska J.V. Pseudomembranous colitis: the experimental induction of the disease with Staphylococcus aureus and its enterotoxin. AMA Arch. Surg. 1959, 79:197-206.
81. Pinchuk I.V., et al. Staphylococcal enterotoxins. Toxins (Basel) 2010, 2:2177-2197.
82. Varshney A.K., et al. Diverse enterotoxin gene profiles among clonal complexes of Staphylococcus aureus isolates from the Bronx, New York. Appl. Environ. Microbiol. 2009, 75:6839-6849.
83. Le Loir Y., et al. Staphylococcus aureus and food poisoning. Genet. Mol. Res. 2003, 2:63-76.
84. Argudin M.A., et al. Food poisoning and Staphylococcus aureus enterotoxins. Toxins (Basel) 2010, 2:1751-1773.
85. Larkin E.A., et al. Staphylococcus aureus: the toxic presence of a pathogen extraordinaire. Curr. Med. Chem. 2009, 16:4003-4019.
86. Shupp J.W., et al. Identification of a transcytosis epitope on staphylococcal enterotoxins. Infect. Immun. 2002, 70:2178-2186.
87. Alonzo F., et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013, 493:51-55.
88. Reyes-Robles T., et al. Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection. Cell Host Microbe 2013, 14:453-459.
89. Alonzo F., et al. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol. Microbiol. 2012, 83:423-435.
90. Schneditz G., et al. Enterotoxicity of a nonribosomal peptide causes antibiotic-associated colitis. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:13181-13186.
91. Darby A., et al. Cytotoxic and pathogenic properties of Klebsiella oxytoca isolated from laboratory animals. PLoS ONE 2014, 9:e100542.
92. Minami J., et al. Biological activities and chemical composition of a cytotoxin of Klebsiella oxytoca. J. Gen. Microbiol. 1992, 138:1921-1927.
93. El Feghaly R.E., et al. Viral co-infections are common and are associated with higher bacterial burden in children with Clostridium difficile infection. J. Pediatr. Gastroenterol. Nutr. 2013, 57:813-816.
94. Florescu D.F., et al. Clostridium difficile and cytomegalovirus colitis co-infection: search for the hidden 'bug'. Transpl. Infect. Dis. 2011, 13:411-415.
95. John S.G., et al. A rare case intractable diarrhea secondary to Clostridium difficile and cytomegalovirus coinfection. Am. J. Case Rep. 2013, 14:498-501.
96. Ludwig A., et al. Concurrent outbreaks with co-infection of norovirus and Clostridium difficile in a long-term-care facility. Epidemiol. Infect. 2013, 141:1598-1603.
97. Lukkarinen H., et al. Clostridium difficile ribotype 027-associated disease in children with norovirus infection. Pediatr. Infect. Dis. J. 2009, 28:847-848.
98. Valentini D., et al. Coinfection in acute gastroenteritis predicts a more severe clinical course in children. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32:909-915.
99. Borriello S.P., et al. Diarrhoea and simultaneous excretion of Clostridium difficile cytotoxin and C. perfringens enterotoxin. Lancet 1984, 2:1218.
100. Vervoort J., et al. High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33:2215-2221.
101. Warny M., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
102. Smedley J.G., et al. Identification of a prepore large-complex stage in the mechanism of action of Clostridium perfringens enterotoxin. Infect. Immun. 2007, 75:2381-2390.
103. Hennekinne J.A., et al. Staphylococcus aureus and its food poisoning toxins: characterization and outbreak investigation. FEMS Microbiol. Rev. 2012, 36:815-836.
104. Llewelyn M., Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect. Dis. 2002, 2:156-162.